Desfatigan (Calcium Pangamate) may be part of symptomatic management applied across domains where additional symptomatic support is needed in contexts marked by generalized low energy and physical fatigue. The preparation is relevant for easing symptom clusters that may become intense or disruptive, associated with chronic or situational weakness.

It is relevant to note the status of this compound. Pangamic Acid (or Vitamin B15/Calcium Pangamate products) is characterized by a lack of established identity and scientific evidence supporting claimed benefits or nutritional properties, leading to its classification as unsafe for food and drug use in various regulatory contexts. Despite this, the substance is used for the following supportive purposes.

The preparation is applied in addressing symptom clusters related to persistent lassitude, functional weakness (asthenia), and impaired physical stamina. The compound is commonly used to help with supporting the body’s ability to sustain effort and may assist with recovery from noticeable physiological strain. This provides supportive relief when symptoms interfere with routine activities, such as during post-convalescence asthenia or periods of prolonged physical commitment. The supportive therapeutic benefit helps ease the overall symptom burden, contributing to improved day-to-day comfort.

---

Quick Fact: Supportive Contexts
Therapeutic Domain: Supportive management of asthenia
Symptom Focus: Persistent lassitude and reduced endurance
Contextual Use: Convalescence and high physical demand scenarios
Core Benefit: Assists with maintaining functional stability and coping with weakness

Who can and cannot use Desfatigan?

The population eligibility for Desfatigan (Pangamate Calcium) is highly restrictive, largely defined by the compound's regulatory status as an unsafe and unapproved drug in major jurisdictions, lacking established identity and scientific evidence.

Category	Official Regulatory Statement
Populations for whom use is allowed	None. The substance is classified as an unsafe and unapproved drug, prohibiting its official use by any population under standard labeled conditions.
Populations for whom use is contraindicated	All individuals in jurisdictions where the substance is designated as an unsafe and unapproved drug.

The official eligibility documents also specify non-eligibility for certain patient groups:

• Condition-Specific Contraindications: Individuals with existing renal impairment or kidney conditions are advised against use due to the potential to cause or aggravate serious kidney problems, including stones.
• Pregnancy and Lactation: Use is considered UNSAFE and is formally advised against during both pregnancy and breastfeeding.
• Age-Related Eligibility: Eligibility is not established for pediatric (children and adolescents) or geriatric (older adults) populations, as a validated safety and efficacy profile is absent.

Regulatory documents establish that no population has a verified safety and efficacy profile, and they specifically document non-eligibility for individuals with kidney impairment and for those who are pregnant or breastfeeding.

The interaction profile for Desfatigan (Pangamate Calcium) is defined by its official regulatory status, which strictly limits the availability of formal interaction data. Government health authorities require robust, approved drug labeling to document specific drug-drug interactions, including metabolic pathways, timing rules, and contraindicated combinations. However, in key jurisdictions such as the United States, the U.S. Food and Drug Administration officially classifies Pangamic Acid products as generally unsafe for drug use. This regulatory determination precludes the establishment of a formal, government-verified interaction section in approved prescribing information. As a result, no specific, officially documented interaction entities are available to populate the standard regulatory profile. The following table reflects the information as available in authoritative government documentation:

Category	Official Regulatory Statement
Documented Interactions	No specific drug-drug, drug-food, or drug-supplement interactions are explicitly documented in official government drug labels (SmPC, PI, or equivalent).
Timing/Separation Rules	No mandatory requirements for the timing or separation of administration are documented in official labels.
Pharmacokinetic Data	No specific CYP450-mediated or transporter interactions are documented in official regulatory labels.
Contraindications	No combinations are formally listed as contraindicated in official government drug labels.

The overall interaction structure is formally characterized by the absence of a government-approved interaction profile. This lack of a documented structure confirms that no specific, verifiable restrictions are officially recorded in regulatory documents for co-administration with other medicines or products.

Selective Potentiation of Serotonin Signaling

Desfatigan's mechanism starts with its role as an inhibitor, primarily targeting the Serotonin Transporter (SERT) protein in the brain. By selectively blocking this transporter, the drug prevents the rapid reabsorption of serotonin from the synaptic cleft into the presynaptic neuron. This action immediately and significantly increases the availability of the signal-carrying neurotransmitter in the synaptic cleft.

Systemic Adaptation of Neural Circuits

The prolonged, elevated presence of serotonin in the synapse initiates a critical, time-dependent process of neural adaptation. This involves cellular changes like altering the sensitivity and density of postsynaptic receptors, which leads to alterations in the responsiveness of entire neural circuits. These adaptations constitute a long-term change in the dynamic equilibrium of neurotransmitter activity.

Secondary Transporter and Receptor Modulation

Beyond its primary target, the drug also demonstrates minor interaction with the Norepinephrine Transporter (NET) and exhibits binding affinity for the Sigma-1 receptor. These secondary mechanistic domains contribute to the overall spectrum of physiological changes by introducing subtle modulation across other signaling pathways.

Official Administration Guidelines

Desfatigan (Pangamate Calcium) is utilized in clinical practice according to specific administration rules. These instructions cover both the method of delivery and the precise scheduling of the medicine.

---

Administration Scope and Dosing

The medicine is formally available as tablets for oral intake and as a solution for injection for parenteral administration, typically administered intramuscularly (IM) or intravenously (IV).

Category	General Administration Instructions
Route of Administration	Oral or Parenteral (IM/IV) methods are authorized.
Standard Dosing	Oral doses often start from 50 mg to 100 mg daily, with maintenance doses potentially reaching 300 mg daily, administered in divided amounts. The parenteral dose is typically 100 mg once daily.
Timing Relative to Meals	Oral preparations are generally taken independently of meals (with or without food).

---

Procedural Use and Scheduling

Usage of Desfatigan is defined by a cyclical protocol, not continuous long-term use. This approach dictates a specific sequence and duration for administration:

• Course Duration: The medicine is intended for a defined course of treatment, often lasting between 3 to 6 weeks, as described in prescribing information.
• Cyclic Use: Following the completion of a treatment course, a mandatory rest period of 1 to 3 months is generally required before a new cycle can be initiated.
• Parenteral Conditions: The solution for injection must be visually clear and colorless before use, and its administration must be performed by or under the supervision of a healthcare professional.

These instructions define the standardized requirements for using the medicine, ensuring adherence to the intended route, dose ranges, and cyclical pattern.

Research Evidence / Overview of Studies for Desfatigan

Evidence for Supportive Use in Functional Weakness and General Fatigue

The compound Pangamate Calcium (Desfatigan) was studied to evaluate observations in contexts marked by general fatigue and functional weakness, which are outcomes related to systemic or functional imbalance. Research in this area is characterized by older, small-scale clinical studies and observational reports, primarily conducted in past decades. These studies typically involved adult cohorts and in these studies, researchers monitored patient-reported outcomes describing perceived discomfort and shifts in physical stamina. Beyond human reports, much of the research base derives from laboratory studies using animal models. The findings help contextualize how patients reported their experience, but research does not determine whether an individual will respond similarly to the animal or in vitro models.

---

Evidence Landscape: Quality of Research and Regulatory Stance

The scientific evidence quality varies across studies and is widely considered to be limited. A major gap is the lack of modern, large-scale, placebo-controlled randomized controlled trials (RCTs), which are required by regulators to establish the scientific certainty of observations. The U.S. Food and Drug Administration (FDA) has historically determined that Pangamic Acid products are generally considered unsafe for drug use due to a lack of established identity and accepted scientific evidence to support claimed benefits. This regulatory stance reflects the overall low certainty that remains in the scientific community.

---

What Is Still Uncertain About Desfatigan Research

Long-term effects are not fully established, and follow-up durations were limited in the available reports. Data concerning the use of the compound in specific human subgroups—such as older adults, children, or those with complex comorbid conditions—remain insufficient to draw conclusions. The most significant uncertainty is the critical absence of modern, methodologically sound trials designed to meet current global regulatory standards.

Common questions about Desfatigan (FAQ)

Q: Is Desfatigan a common or widely-used medication?

According to regulatory documentation, the U.S. Food and Drug Administration (FDA) classifies the substance known as Desfatigan (Pangamate Calcium) as an unsafe and unapproved drug.

Because of its regulatory status and prohibition from being introduced into commerce as a drug in the U.S., it is not widely available as a regulated prescription medication in that jurisdiction.

Q: Is the medication designed to be taken at a specific time of day?

Official administration guidelines describe that oral tablets are generally taken independently of meals, meaning they can be consumed with or without food.

However, official product information does not mandate a specific time of day, such as morning or evening, for the medicine's administration.

Q: Is it normal to feel a mild headache or dizziness when first starting Desfatigan?

The official regulatory safety profile for this substance does not include a typical, classified list of common or mild adverse events, such as headache or dizziness.

This is because major authorities, such as the U.S. FDA, have not approved the product as a drug and therefore have not established a standard adverse event profile.

Q: Can Desfatigan affect the results of any lab tests?

Official safety information does not specifically document interference with the results of lab tests. However, regulatory documents do note concerns regarding potential problems in the kidney, including the formation of kidney stones.

Kidney function, which may be impacted by this condition, is generally assessed through routine lab tests. Official information does not specify interference with test results.

Q: Are there different brand names for the same medicine, Desfatigan?

Desfatigan is the commercial designation for the preparation. The active compound within it is Pangamate Calcium.

This substance is also widely known by the historical, though scientifically disputed, name Vitamin B15.

How to Store and Dispose of Desfatigan?

Official regulatory guidelines strictly define the conditions for storing and disposing of Desfatigan (Pangamate Calcium) to maintain its quality and prevent harm.

Storage Requirements

Desfatigan must be stored at a controlled room temperature (typically 20 °C to 25 °C or 68 °F to 77 °F) and must not be frozen. The product requires protection from light and excessive moisture; therefore, it must be kept in the original container and maintained tightly closed.

Critically, the medicine must be stored out of the sight and reach of children to comply with mandatory safety regulations.

Disposal Instructions

Unused or expired Desfatigan should be disposed of through an authorized drug take-back program if one is available. If not, the medicine should be mixed with an undesirable substance, placed in a sealed container, and thrown into household trash. The product must not be flushed down a toilet or poured down a sink.